Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Schmitt, Wilhelm [VerfasserIn]   i
 Hagen, E. Christiaan [VerfasserIn]   i
 Neumann, Irmgard [VerfasserIn]   i
 Nowack, Rainer [VerfasserIn]   i
 Flores-Suárez, Luis Felipe [VerfasserIn]   i
 Woude, Fokko J. van der [VerfasserIn]   i
Titel:Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG)
Titelzusatz:an open study in 15 patients
Verf.angabe:Wilhelm H. Schmitt, E. Christiaan Hagen, Irmgard Neumann, Rainer Nowack, Luis Felipe Flores-Suárez, and Fokko J. van der Woude for the European Vasculitis Study Group
Jahr:2004
Umfang:9 S.
Fussnoten:Gesehen am 22.06.2022
Titel Quelle:Enthalten in: Kidney international
Ort Quelle:New York, NY : Elsevier, 1972
Jahr Quelle:2004
Band/Heft Quelle:65(2004), 4, Seite 1440-1448
ISSN Quelle:1523-1755
Abstract:BACKGROUND: A subset of patients with Wegener's granulomatosis does not respond sufficiently to cyclophosphamide and glucocorticosteroids or suffers of intolerable side effects. Anecdotal data suggest that antithymocyte globulin (ATG) may be a treatment option for these patients. We now describe 15 patients treated with ATG for refractory Wegener's granulomatosis. METHODS: Fifteen patients with histologically proven active refractory Wegener's granulomatosis (seven unresponsive to cyclophosphamide, eight intolerant) were treated with ATG by a protocol (SOLUTION protocol) designed by the European Vasculitis Study (EUVAS) Group. RESULTS: Before ATG administration, patients had received a mean of 5.2 (range 2 to 7) different therapeutic approaches including glucocorticosteroids and cyclophosphamide in all and experimental therapies in six, without control of disease activity [2.8 (range 1 to 7) relapses during a disease duration of 63.2 (range 18 to 180) months]. Thirteen of 15 patients showed a favorable response to ATG with partial (N= 9) or complete (N= 4) remission. During a follow-up of 21.8 (range 6 to 68) months, seven patients relapsed after a mean of 8.4 (range 2 to 24) months (five minor and two major relapses). Six patients are free of relapse for 22.3 (range 7 to 64) months. Two patients died, 1 and 3 days following the first dose of ATG, due to pulmonary hemorrhage and infection (one each). Although further immunosuppressive treatment was required in all surviving patients, a less intensive regimen could be applied in 12. Beside fever and chills associated with the first gift of ATG, ATG was well tolerated, with infections being observed in five cases and serum sickness in two. CONCLUSION: Anti-T-cell-directed treatment with ATG may be a therapeutic option for severe refractory Wegener's granulomatosis if simultaneous infections and fluid overload have been ruled out. In patients with alveolar hemorrhage, ATG should only be used under special caution.
DOI:doi:10.1111/j.1523-1755.2004.00534.x
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1111/j.1523-1755.2004.00534.x
 Volltext: https://www.sciencedirect.com/science/article/pii/S0085253815498564
 DOI: https://doi.org/10.1111/j.1523-1755.2004.00534.x
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Adult
 Antilymphocyte Serum
 Cyclophosphamide
 Female
 Glucocorticoids
 Granulomatosis with Polyangiitis
 Humans
 Immunosuppressive Agents
 Male
 Middle Aged
 Prospective Studies
 Retreatment
 Treatment Outcome
K10plus-PPN:1807457109
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68933494   QR-Code
zum Seitenanfang